Electromed, Inc. Announces Formation of Bronchiectasis Advisory Board
August 22 2017 - 4:05PM
Business Wire
Electromed, Inc. (NYSE MKT: ELMD) today announced that it has
formed a bronchiectasis advisory board composed of three renowned
experts in pulmonary medicine. The bronchiectasis advisory board
will serve as a key strategic resource to advance bronchiectasis
awareness and help guide the development of clinical research plans
and future airway clearance therapy innovations.
The members of the board include:
- Chad Marion, DO, PhD, is an Assistant
Professor and Associate Director of the Adult Cystic Fibrosis
Program of Medicine at Wake Forest Baptist Health and
board-certified in Internal Medicine and Pulmonary Disease. Dr.
Marion’s research interests include cystic fibrosis, non-CF
bronchiectasis, opportunistic infections of the lung, bacteria,
pneumonia, respiratory tract infections, gram-negative bacterial
infections, and sepsis.
- Peadar Noone, MD, FCCP, FRCPI, DCH,
MRCGP, is a Professor of Medicine and Medical Director for the
University of North Carolina Center for Bronchiectasis Care.
Dr. Noone's scholarly activities include national and international
clinical expertise in cystic fibrosis, primary ciliary dyskinesia,
non-CF bronchiectasis, and nontuberculous mycobacterial lung
infections.
- Anne O’Donnell, MD, is the Professor of
Medicine and Chief, Division of Pulmonary, Critical Care, and Sleep
Medicine at Georgetown University Medical Center. Dr. O’Donnell’s
special interests include bronchiectasis, respiratory infections,
including nontuberculous mycobacterium, sleep apnea and sleep
disorders, cystic fibrosis, and non-invasive ventilation.
“Electromed is committed to engaging clinicians, payers and
patients with evidence-based information to advance bronchiectasis
awareness,” commented Kathleen Skarvan, President and Chief
Executive Officer of Electromed. “We are thrilled to have Dr.
Noone, Dr. O’Donnell, and Dr. Marion – global thought leaders in
the field of pulmonary medicine – join the Electromed
bronchiectasis advisory board. In collaboration with these
distinguished physicians, Electromed will continue to focus on
educating the healthcare community on the effectiveness and value
of airway clearance therapy in improving patients’ quality of life
and reducing bronchiectasis healthcare utilization and associated
costs.”
About Electromed, Inc.
Electromed manufactures, markets, and sells products that
provide airway clearance therapy, including the SmartVest® Airway
Clearance System, to patients with compromised pulmonary function.
It is headquartered in New Prague, Minnesota and founded in 1992.
Further information about Electromed can be found at
www.smartvest.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170822006024/en/
Electromed, Inc.Kathleen Skarvan, 952-758-9299President and
Chief Executive Officerkskarvan@electromed.com
Electromed (AMEX:ELMD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Electromed (AMEX:ELMD)
Historical Stock Chart
From Apr 2023 to Apr 2024